查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1607159

胃肠道疾病治疗药物市场：按分销管道、给药途径和应用划分 - 全球预测 2025-2030

Gastrointestinal Diseases Therapeutics Market by Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), Route of Administration (Intravenous, Oral), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年胃肠道疾病治疗市值为401.8亿美元，预计到2024年将达到418.2亿美元，复合年增长率为4.00%，到2030年将达到529.1亿美元。

胃肠道疾病治疗市场包括针对消化器官系统疾病的治疗解决方案的开发、生产和开拓，包括但不限于发炎性肠道疾病肠道疾病、大肠激躁症躁症、克隆氏症和胃食道逆流症。由于不良饮食、久坐的生活方式和人口老化等因素，全球消化器官系统疾病盛行率不断上升，这个市场变得至关重要。治疗应用包括生技药品、小分子、酸中和剂和酵素补充剂，为包括医院、诊所和专科医疗中心在内的各种最终用户提供服务。该市场受到生物技术快速发展、个人化医疗需求不断增长以及强大的创新治疗管道的影响。机会包括开发生物相似药、探索基于微生物的治疗方法以及扩展到医疗基础设施正在改善的新兴市场。新的治疗领域，例如针对肠-脑相互作用的神经调节药物，是技术创新的一个有前途的前沿领域。然而，市场面临药物开发高成本、监管要求严格以及学名药製造商的竞争压力等挑战。此外，由于复杂的治疗方法和潜在的副作用，患者的依从性仍然是一个问题。为了克服这些挑战，公司正在专注于建立研发策略伙伴关係，投资数位健康技术以提高病人参与，并利用现实世界的证据简化临床试验。创新的关键领域是整合人工智慧和机器学习，以加速药物发现并提高诊断能力。动态的市场条件、不断变化的监管环境和不断变化的患者需求需要专注于敏捷策略和持续的研究和开发。透过专注于这些方法，公司可以提高其市场地位，并为全球对抗胃肠道疾病做出贡献。

主要市场统计
基准年[2023] 401.8亿美元
预测年份 [2024] 418.2亿美元
预测年份 [2030] 529.1亿美元
复合年增长率（%） 4.00%

市场动态：快速发展的胃肠道药物市场的关键市场洞察

胃肠道疾病药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 胃肠道疾病盛行率增加
    • 对自我治疗和再生医学的需求不断增长
    • 越来越多地采用生技药品治疗胃肠道疾病
  • 市场限制因素
    • 与胃肠道疾病相关的社会经济负担增加
  • 市场机会
    • 药厂加大研发投入
    • 政府预防和​​治疗胃肠道疾病的倡议
  • 市场挑战
    • 专利到期增加

波特五力：驾驭胃肠道药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解胃肠道疾病治疗市场的外部影响

外部宏观环境因素在塑造胃肠道疾病治疗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解胃肠疾病治疗药物市场竞争状况

胃肠疾病治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵胃肠道疾病治疗市场供应商绩效评估

FPNV定位矩阵是评估胃肠道疾病治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划胃肠疾病药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对胃肠道疾病药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 胃肠道疾病盛行率增加
      • 对自我治疗和再生医学的需求不断增长
      • 越来越多地采用生物製药治疗胃肠道疾病
    • 抑制因素
      • 与胃肠道疾病相关的社会经济负担日益增加
    • 机会
      • 药厂加大研发投入
      • 政府预防和​​治疗胃肠道疾病的倡议
    • 任务
      • 专利到期时间增加
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章消化系统疾病治疗药物市场：依通路分类

  • 医院药房
  • 网路药房
  • 零售药房

第七章胃肠道疾病治疗药物市场：依给药途径分类

  • 静脉
  • 口服

第八章消化系统疾病治疗药物市场：依应用分类

  • 克隆氏症
  • 胃食道逆流症
  • 溃疡性大肠炎

第九章北美和南美消化系统疾病治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太消化疾病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲胃肠道疾病治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla Inc.
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Olympus Corporation
  • Ovesco Endoscopy AG
  • Takeda Pharmaceutical Company Limited
  • UCB SA
Product Code: MRR-957C47F91DC1

The Gastrointestinal Diseases Therapeutics Market was valued at USD 40.18 billion in 2023, expected to reach USD 41.82 billion in 2024, and is projected to grow at a CAGR of 4.00%, to USD 52.91 billion by 2030.

The gastrointestinal diseases therapeutics market encompasses the development, production, and distribution of therapeutic solutions targeting ailments of the digestive system, including but not limited to inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, and gastroesophageal reflux disease. This market is indispensable due to the rising prevalence of digestive disorders globally, attributed to factors such as poor dietary habits, sedentary lifestyles, and a growing aging population. Therapeutic applications include biologics, small molecules, acid neutralizers, and enzyme replacements, serving diverse end-users like hospitals, clinics, and specialized care centers. The market is influenced by rapid advancements in biotechnology, increasing demand for personalized medicine, and a strong pipeline of innovative treatments. Opportunities lie in the development of biosimilars, the exploration of microbiome-based therapies, and the expansion into emerging markets where healthcare infrastructure is improving. New therapeutic areas, such as neuromodulators targeting gut-brain interactions, represent a promising frontier for innovation. However, the market faces challenges, including high costs associated with drug development, stringent regulatory requirements, and competitive pressure from generic drug manufacturers. Additionally, patient adherence remains a concern due to complex treatment regimens and potential side effects. To navigate these challenges, companies should focus on building strategic partnerships for research and development, investing in digital health technologies to improve patient engagement, and streamlining clinical trials using real-world evidence. A significant area for innovation lies in integrating artificial intelligence and machine learning to accelerate drug discovery and improve diagnostic capabilities. The market is dynamic, with fluctuating regulatory landscapes and evolving patient needs, necessitating agile strategies and an emphasis on continuous research and development. By focusing on these approaches, companies can enhance their market position and contribute to the global fight against gastrointestinal ailments.

KEY MARKET STATISTICS
Base Year [2023] USD 40.18 billion
Estimated Year [2024] USD 41.82 billion
Forecast Year [2030] USD 52.91 billion
CAGR (%) 4.00%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gastrointestinal Diseases Therapeutics Market

The Gastrointestinal Diseases Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of gastrointestinal diseases
    • Rising demand for self-medication and regenerative medicines
    • Increasing adoption of biologics for treatment of gastrointestinal diseases
  • Market Restraints
    • Rising socio-economic burden associated with GI disorders
  • Market Opportunities
    • Rising investments in R&D by pharmaceutical companies
    • Government initiatives to prevent and treat gastrointestinal diseases
  • Market Challenges
    • Increasing number of patent expirations

Porter's Five Forces: A Strategic Tool for Navigating the Gastrointestinal Diseases Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gastrointestinal Diseases Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gastrointestinal Diseases Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gastrointestinal Diseases Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gastrointestinal Diseases Therapeutics Market

A detailed market share analysis in the Gastrointestinal Diseases Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gastrointestinal Diseases Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gastrointestinal Diseases Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gastrointestinal Diseases Therapeutics Market

A strategic analysis of the Gastrointestinal Diseases Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastrointestinal Diseases Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Cipla Inc., Eisai Co. Ltd., Eli Lilly and Company, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Novartis AG, Olympus Corporation, Ovesco Endoscopy AG, Takeda Pharmaceutical Company Limited, and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Gastrointestinal Diseases Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Route of Administration, market is studied across Intravenous and Oral.
  • Based on Application, market is studied across Crohn's Disease, Gastroesophageal Reflux Disease, and Ulcerative Colitis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of gastrointestinal diseases
      • 5.1.1.2. Rising demand for self-medication and regenerative medicines
      • 5.1.1.3. Increasing adoption of biologics for treatment of gastrointestinal diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Rising socio-economic burden associated with GI disorders
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising investments in R&D by pharmaceutical companies
      • 5.1.3.2. Government initiatives to prevent and treat gastrointestinal diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Increasing number of patent expirations
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gastrointestinal Diseases Therapeutics Market, by Distribution Channel

  • 6.1. Introduction
  • 6.2. Hospital Pharmacies
  • 6.3. Online Pharmacies
  • 6.4. Retail Pharmacies

7. Gastrointestinal Diseases Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral

8. Gastrointestinal Diseases Therapeutics Market, by Application

  • 8.1. Introduction
  • 8.2. Crohn's Disease
  • 8.3. Gastroesophageal Reflux Disease
  • 8.4. Ulcerative Colitis

9. Americas Gastrointestinal Diseases Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gastrointestinal Diseases Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gastrointestinal Diseases Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. Biogen Inc.
  • 5. Boehringer Ingelheim International GmbH
  • 6. Cipla Inc.
  • 7. Eisai Co. Ltd.
  • 8. Eli Lilly and Company
  • 9. GlaxoSmithKline PLC
  • 10. Johnson & Johnson Services Inc.
  • 11. Novartis AG
  • 12. Olympus Corporation
  • 13. Ovesco Endoscopy AG
  • 14. Takeda Pharmaceutical Company Limited
  • 15. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023